Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report.

Karimi, Mehran; Zarei, Tahereh; Haghpanah, Sezaneh; Azarkeivan, Azita; Naderi, Maryam; Matin, Sara; Bazrafshan, Asghar; Zahedi, Zohreh; Shirkavand, Afshan; Pishdad, Parisa; De Sanctis, Vincenzo

Karimi, Mehran; Zarei, Tahereh; Haghpanah, Sezaneh; Azarkeivan, Azita; Naderi, Maryam; Matin, Sara; Bazrafshan, Asghar; Zahedi, Zohreh; Shirkavand, Afshan; Pishdad, Parisa; De Sanctis, Vincenzo.

Afiliação

Karimi M; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zarei T; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Haghpanah S; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Azarkeivan A; Zafar Adult Thalassemia Clinic, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Naderi M; Iranian Blood Transfusion Organization Research Center, Thalassemia Clinic, Tehran, Iran.
Matin S; Pediatric Department, Jahrom University of Medical Sciences, Jahrom, Iran.
Bazrafshan A; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahedi Z; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Shirkavand A; Laser Medicine Research group, MLRC, Yara institute, ACECR; Medical physicist, Pardis Noor Medical Imaging Center, Tehran, Iran.
Pishdad P; Medical Imaging Research Center, Department of Radiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
De Sanctis V; Coordinator of ICET-A Network (International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine) and Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy.

Mediterr J Hematol Infect Dis ; 14(1): e2022026, 2022.

Article em En | MEDLINE | ID: mdl-35444764

Palavras-chave

Adverse events; Breakthrough SARS-CoV-2 infection; Efficacy; Hemoglobinopathies; Safety; Sinopharm vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Mediterr J Hematol Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google